

Corrections

Ertugliflozin for type 2 diabetes [Correction]

Aust Prescr 2019;42:115

<https://doi.org/10.18773/austprescr.2019.036>

First published 26 April 2019

The new drug commentary on ertugliflozin (*Aust Prescr 2019;42:70-2*) has been corrected.

The paragraph on lower limb amputations cited incorrect figures. The original text “Lower limb amputations were more common in people receiving ertugliflozin (0.47% with 5 mg dose, 0.26% with 15 mg dose) than those who did not receive it (0.07%). This has previously been found with canagliflozin which is no longer registered for use in Australia.” has been replaced with “Lower limb amputations were more common in people receiving the higher ertugliflozin dose (0.47% with 15 mg dose) than those who received the lower dose (0.06% with 5 mg dose) or the comparator (0.07%). Lower limb amputations have previously been found with canagliflozin which is no longer registered for use in Australia.”

Influenza: overview on prevention and therapy [Correction]

Aust Prescr 2019;42:115

<https://doi.org/10.18773/austprescr.2019.045>

The article on Influenza (*Aust Prescr 2019;42:51-5*) has been corrected.

The paragraph on National Immunisation Program funding for people at increased risk of influenza morbidity and mortality should have included ‘Aboriginal and Torres Strait Islanders aged over six months and over’ (rather than just ‘Aboriginal and Torres Strait Islander children aged six months to five years’ and ‘Aboriginal and Torres Strait Islanders aged over 15 years’).

A:

ANSWERS TO SELF-TEST QUESTIONS

- | | |
|---------|---------|
| 1 True | 2 False |
| 3 False | 4 False |

EDITORIAL OFFICE

For general correspondence such as Letters to the Editor, contact the Editor.

Postal The Editor
Australian Prescriber
 Level 5, 15 Moore Street
 Canberra, ACT 2600

Telephone +61 2 8217 8700

Email info@australianprescriber.com

Website nps.org.au/australian-prescriber

Twitter @AustPrescriber

SUBSCRIPTIONS

Australian Prescriber is published every two months online. All content is accessible free of charge in full text at nps.org.au/australian-prescriber. New drugs are published between issues as they become available.

An email alert can be sent to you when *Australian Prescriber* publishes new material. Subscribe or update your details at nps.org.au/australian-prescriber

For back issues, and copies of the Anaphylaxis wallchart and Switching-antidepressants poster, email info@australianprescriber.com

© 2019 NPS MedicineWise
 ABN 61 082 034 393

NPS MedicineWise Disclaimer

Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information.